APA (7th ed.) Citation

Shota Takahashi, M., Yuki Sato, M., Yoshiharu Sato, P., Ryosuke Hirabayashi, M., Shigeo Hara, M., Yutaka Takahashi, M., & Keisuke Tomii, M. (2024, February). Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From EGFR-Mutated Adenocarcinoma After Osimertinib Treatment: A Case Report. JTO Clinical and Research Reports.

Chicago Style (17th ed.) Citation

Shota Takahashi, MD, MD Yuki Sato, PhD Yoshiharu Sato, MD Ryosuke Hirabayashi, MD Shigeo Hara, MD Yutaka Takahashi, and MD Keisuke Tomii. "Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From EGFR-Mutated Adenocarcinoma After Osimertinib Treatment: A Case Report." JTO Clinical and Research Reports Feb. 2024.

MLA (9th ed.) Citation

Shota Takahashi, MD, et al. "Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From EGFR-Mutated Adenocarcinoma After Osimertinib Treatment: A Case Report." JTO Clinical and Research Reports, Feb. 2024.